Helminth-derived molecules improve 5-fluorouracil treatment on experimental colon tumorigenesis
Biomed Pharmacother. 2024 Apr 24;175:116628. doi: 10.1016/j.biopha.2024.116628. Online ahead of print.ABSTRACTColorectal cancer (CRC) is one of the most prevalent fatal neoplasias worldwide. Despite efforts to improve the early diagnosis of CRC, the mortality rate of patients is still nearly 50%. The primary treatment strategy for CRC is surgery, which may be accompanied by chemotherapy and radiotherapy. The conventional and first-line chemotherapeutic agent utilized is 5-fluorouracil (5FU). However, it has low efficiency. Combination treatment with leucovorin and oxaliplatin or irinotecan improves the effectiveness of 5FU...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 25, 2024 Category: Drugs & Pharmacology Authors: M ónica G Mendoza-Rodríguez Daniela Medina-Reyes Cuauht émoc A Sánchez-Barrera Karen V Fern ández-Muñoz Ver ónica García-Castillo Jorge L Ledesma-Torres Marisol I Gonz ález-González Jos é L Reyes Carlos P érez-Plascencia Miriam Rodr íguez-Sos Source Type: research
Microcystin-LR Improves Anti-Tumor Efficacy of Oxaliplatin through Induction of M1 Macrophage Polarization
In this study, we used microcystin-LR (MC-LR), a cyclic heptapeptide produced by cyanobacteria, to induce in vitro macrophage innate immunity and transition into the anti-tumor M1 phenotype. MC-LR was also tested in vivo in a mouse model of colorectal cancer. An intraperitoneal injection of MC-LR increased the proportion of CD86⁺ M1 macrophages and triggered the maturation of CD11c⁺ dendritic cells within tumor tissues. MC-LR combined with the chemotherapeutic drug oxaliplatin significantly inhibited tumor growth in vivo. Flow cytometry analysis revealed increased infiltration of activated cytotoxic (CD8⁺, PD-1⁺) T...
Source: Toxicon - April 25, 2024 Category: Toxicology Authors: Li Keyi Minzhu Yang Yuxin Dai Jinyan Huang Peng Zhu Liu Qiuzhen Source Type: research
The Molecular Characteristics and Therapeutic Implications of O-Glycan Synthesis in Pancreatic Cancer by Integrating Transcriptome and Single-Cell Data
CONCLUSION: We first constructed molecular subtypes and prognostic models related to O-glycan biosynthesis in PC. It is clear that O-glycan biosynthesis is related to the development, prognosis, immune microenvironment, and treatment of PC. This provides new strategies for stratification, diagnosis, and treatment of PC patients.PMID:38659264 | DOI:10.2174/0109298673293445240409060446 (Source: Current Medicinal Chemistry)
Source: Current Medicinal Chemistry - April 25, 2024 Category: Chemistry Authors: Binqian Huang Biao Zhang Jifeng Liu Tingxin Wang Yunshu Zhang Bolin Zhang Qihang Yuan Shilin Xia Dong Shang Source Type: research
Helminth-derived molecules improve 5-fluorouracil treatment on experimental colon tumorigenesis
Biomed Pharmacother. 2024 Apr 24;175:116628. doi: 10.1016/j.biopha.2024.116628. Online ahead of print.ABSTRACTColorectal cancer (CRC) is one of the most prevalent fatal neoplasias worldwide. Despite efforts to improve the early diagnosis of CRC, the mortality rate of patients is still nearly 50%. The primary treatment strategy for CRC is surgery, which may be accompanied by chemotherapy and radiotherapy. The conventional and first-line chemotherapeutic agent utilized is 5-fluorouracil (5FU). However, it has low efficiency. Combination treatment with leucovorin and oxaliplatin or irinotecan improves the effectiveness of 5FU...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 25, 2024 Category: Drugs & Pharmacology Authors: M ónica G Mendoza-Rodríguez Daniela Medina-Reyes Cuauht émoc A Sánchez-Barrera Karen V Fern ández-Muñoz Ver ónica García-Castillo Jorge L Ledesma-Torres Marisol I Gonz ález-González Jos é L Reyes Carlos P érez-Plascencia Miriam Rodr íguez-Sos Source Type: research
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
British Journal of Cancer, Published online: 25 April 2024; doi:10.1038/s41416-024-02696-6First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial (Source: British Journal of Cancer)
Source: British Journal of Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Anne Hansen Ree J ūratė Šaltytė Benth Hanne M. Hamre Christian Kersten Eva Hofsli Marianne G. Guren Halfdan Sorbye Christin Johansen Anne Neg ård Tonje Bj ørnetrø Hilde L. Nilsen Jens P. Berg Kjersti Flatmark Sebastian Meltzer Source Type: research
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00896-wThe FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and ...
Source: Nature Reviews Clinical Oncology - April 25, 2024 Category: Cancer & Oncology Authors: Christopher Nevala-Plagemann Ignacio Garrido-Laguna Source Type: research
Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/ β-catenin/GPX4 axis in colorectal cancer
Free Radic Biol Med. 2024 Apr 22:S0891-5849(24)00405-2. doi: 10.1016/j.freeradbiomed.2024.04.226. Online ahead of print.ABSTRACTFusobacterium (F.) nucleatum is a carcinogenesis microbiota in colorectal cancer (CRC). Growing evidence shows that F. nucleatum contributes to chemoresistance. Ferroptosis is reported to restore the susceptibility of resistant cells to chemotherapy. However, the role of gut microbiota affecting ferroptosis in chemoresistance remains unclear. Here, we examined the CRC tissues of patients using 16S rRNA sequencing to investigate the possible connection between gut microbiota dysbiosis and the relap...
Source: Free Radical Biology and Medicine - April 24, 2024 Category: Biology Authors: Bowen Li Zixian Wei Zhiyue Wang Fangqi Xu Jinhua Yang Baiqiang Lin Yu Chen Hubin Wenren Lingli Wu Xiao Guo Yang Liu Yunwei Wei Source Type: research
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
CONCLUSION: Per DLT criteria, binimetinib + pembrolizumab (cohort A) was tolerable, binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, oxaliplatin (cohort C) did not qualify for binimetinib dose escalation to 45 mg, and binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, irinotecan (cohort E) required binimetinib dose reduction from 45 to 30 mg. No new safety findings were observed across cohorts. There was no apparent additive efficacy when binimetinib + pembrolizumab was added to chemotherapy. Data did not support continued enrollment in cohorts C and E.PMID:38653648 | DOI:10.1016/j.clcc.2024.03.002 (Source:...
Source: Clinical Colorectal Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Eric X Chen Petr Kavan Mustapha Tehfe Jeremy S Kortmansky Michael B Sawyer E Gabriela Chiorean Christopher H Lieu Blase Polite Lucas Wong Marwan Fakih Kristen Spencer Jorge Chaves Chenxiang Li Pierre Leconte David Adelberg Richard Kim Source Type: research
Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
CONCLUSIONS: This phenotype/genotype investigation suggests that the FGFR4 p.G388R variant may serve as a new marker for identifying patients who are responsive to TAS-102. A mechanistic hypothesis is proposed to interpret these findings.PMID:38650006 | DOI:10.1186/s12967-024-05184-w (Source: Cancer Control)
Source: Cancer Control - April 22, 2024 Category: Cancer & Oncology Authors: Alessandro Ottaiano Mariachiara Santorsola Monica Ianniello Anna Ceccarelli Marika Casillo Francesco Sabbatino Nadia Petrillo Marco Cascella Francesco Caraglia Carmine Picone Francesco Perri Roberto Sirica Silvia Zappavigna Guglielmo Nasti Giovanni Savare Source Type: research
Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments
Bioorg Chem. 2024 Apr 16;147:107384. doi: 10.1016/j.bioorg.2024.107384. Online ahead of print.ABSTRACTEsophageal squamous cell carcinoma (ESCC) is a malignant tumor that is highly susceptible to metastasis, recurrence and resistance, and few therapeutic targets have been identified and proven effective. Herein, we demonstrated for the first time that Rap1b can positively regulate ESCC cell stemness, as well as designed and synthesized a novel class of Pt(IV) complexes that can effectively inhibit Raplb. In vitro biological studies showed that complex-1 exhibited stronger cytotoxicity than cisplatin and oxaliplatin against ...
Source: Bioorganic Chemistry - April 21, 2024 Category: Chemistry Authors: Jia Zhao Kai Wu Yang Yang Donglei Liu Chunyang Zhang Xiangnan Li Source Type: research
BRAF-mutant microsatellite-stable rectal cancer with acquired KRAS mutation leading to drug resistance in liver metastasis
AbstractBRAF-mutant microsatellite-stable colorectal cancer (CRC), metastasized to distant sites, is associated with a poor prognosis. However, the BEACON CRC regimen, comprising a BRAF inhibitor, MEK inhibitor, and anti-EGFR antibody, offered a prolonged prognosis. Nonetheless, resistance to this regimen may occur, as observed in our reported case of CRC, where aKRAS mutation was identified in addition to theBRAF V600E mutation. Here, we present a case of 74-year-old woman with rectal cancer (pT4bN1bM0 Stage IIIc) harboring theBRAF V600E mutation. After resection of the primary tumor and during adjuvant chemotherapy using...
Source: International Cancer Conference Journal - April 18, 2024 Category: Cancer & Oncology Source Type: research
Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models
RAD54 and BLM helicase play pivotal roles during homologous recombination repair (HRR) to ensure genome maintenance. BLM amino acids (aa 181–212) interact with RAD54 and enhance its chromatin remodeling activity. Functionally, this interaction heightens HRR, leading to a decrease in residual DNA damage in colon cancer cells. This contributes to chemoresistance in colon cancer cells against cisplatin, camptothecin, and oxaliplatin, eventually promoting tumorigenesis in preclinical colon cancer mouse models. ChIP-Seq analysis and validation revealed increased BLM and RAD54 corecruitment on the MRP2 promoter in camptothecin...
Source: Journal of Clinical Investigation - April 15, 2024 Category: Biomedical Science Authors: Ekjot Kaur, Ritu Agrawal, Rimpy Arun, Vinoth Madhavan, Vivek Srivastava, Dilip Kumar, Pragyan Parimita Rath, Nitin Kumar, Sreekanth Vedagopuram, Nishant Pandey, Swati Priya, Patrick Legembre, Samudrala Gourinath, Avinash Bajaj, Sagar Sengupta Source Type: research
Specific IgE and Basophil Activation Test by Microarray: A Promising Tool for Diagnosis of Platinum Compound Hypersensitivity Reactions
This study aimed to evaluate the usefulness of the basophil activation test by flow cytometry (BAT-FC) and the newly developed sIgE-microarray and BAT-microarray in diagnosing IgE-mediated hypersensitivity reactions to PCs. A total of 24 patients with DHRs to PCs (20 oxaliplatin and four carboplatin) were evaluated: thirteen patients were diagnosed as allergic with positive skin tests (STs) or drug provocation tests (DPTs), six patients were diagnosed as non-allergic with negative STs and DPTs, and five patients were classified as suspected allergic because DPTs could not be performed. In addition, four carboplatin-toleran...
Source: Cancer Control - April 13, 2024 Category: Cancer & Oncology Authors: Carlos Fern ández-Lozano Claudia Geraldine Rita Alicia Barra-Castro Bel én de la Hoz Caballer Ernesto Rold án Cristina Pueyo L ópez Javier Martinez-Botas Mar ía Pilar Berges-Gimeno Source Type: research
Novel chromium (III)-based compound for inhibition of oxaliplatin-resistant colorectal cancer progression
This study delved into the potential of a novel chromium (III)-based compound, hexaacetotetraaquadihydroxochromium (III) diiron (III) nitrate, for CRC treatment. The therapeutic promise of this innovative chromium (III)-based compound was explored by utilizing LoVo colon cancer cells and an in-vivo mouse model of CRC. Various dosages of the compound were administered to LoVo parental cells and LoVo oxaliplatin-resistant cells. Findings unveiled that a concentration of 2000 μg/mL of the chromium (III) compound significantly inhibited mesenchymal transition and the migratory and invasive properties of LoVo oxaliplatin-resis...
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Ming-Cheng Chen Hema Sri Devi Hsueh-Fa Pien Shina Fong-Mei Wen Jenn-Line Sheu Bruce Chi-Kang Tsai Chih-Yang Huang Yu-Jung Lin Source Type: research
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
CONCLUSIONS: Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.PMID:38592373 | DOI:10.1158/1078-0432.CCR-24-0027 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Farah Ballout Heng Lu Nadeem Bhat Lei Chen Dunfa Peng Zheng Chen Steven Chen Xiaodian Sun Silvia Giordano Simona Corso Alexander Zaika Oliver McDonald Alan S Livingstone Wael El-Rifai Source Type: research
